Literature DB >> 23520326

MRD in AML: time for redefinition of CR?

Gert Ossenkoppele1, Gerrit Jan Schuurhuis.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23520326     DOI： 10.1182/blood-2013-01-480590

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  14 in total

Review 1.  Bone marrow evaluation for diagnosis and monitoring of acute myeloid leukemia.

Authors:  Mary-Elizabeth Percival; Catherine Lai; Elihu Estey; Christopher S Hourigan
Journal:  Blood Rev       Date:  2017-02-02       Impact factor: 8.250

2.  Leukemic stem cells of acute myeloid leukemia patients carrying NPM1 mutation are candidates for targeted immunotherapy.

Authors:  V Schneider; L Zhang; L Bullinger; M Rojewski; S Hofmann; M Wiesneth; H Schrezenmeier; M Götz; U Botzenhardt; T F E Barth; K Döhner; H Döhner; J Greiner
Journal:  Leukemia       Date:  2014-03-28       Impact factor: 11.528

Review 3.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

4.  Minimal residual disease and stem cell transplantation outcomes.

Authors:  Jacqueline Cloos; Gert J Ossenkoppele; Richard Dillon
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2019-12-06

Review 5.  Clinical Use of Measurable Residual Disease in Acute Myeloid Leukemia.

Authors:  Anne Stidsholt Roug; Hans Beier Ommen
Journal:  Curr Treat Options Oncol       Date:  2019-03-14

Review 6.  Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Authors:  Abraham S Kanate; Marcelo C Pasquini; Parameswaran N Hari; Mehdi Hamadani
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

7.  How do we define complete remission for acute myeloid leukemia in the current era? Results of an international survey.

Authors:  Michael J Burke; Linda Burns; Michael A Linden; Bruce Lindgren; Michael R Verneris; Daniel Weisdorf; Celalettin Ustun
Journal:  Am J Hematol       Date:  2013-06-20       Impact factor: 10.047

Review 8.  Evaluating measurable residual disease in acute myeloid leukemia.

Authors:  Farhad Ravandi; Roland B Walter; Sylvie D Freeman
Journal:  Blood Adv       Date:  2018-06-12

9.  Mesenchymal COX2-PG secretome engages NR4A-WNT signalling axis in haematopoietic progenitors to suppress anti-leukaemia immunity.

Authors:  Limei Wu; Surya Amarachintha; Jian Xu; Frank Oley; Wei Du
Journal:  Br J Haematol       Date:  2018-08-14       Impact factor: 6.998

10.  Clinical significance of day 5 peripheral blast clearance rate in the evaluation of early treatment response and prognosis of patients with acute myeloid leukemia.

Authors:  Cong Yu; Qing-lei Kong; Yun-xiang Zhang; Xiang-qin Weng; Jing Wu; Yan Sheng; Chun-lei Jiang; Yong-mei Zhu; Qi Cao; Shu-min Xiong; Jun-min Li; Xiao-dong Xi; Sai-juan Chen; Bing Chen
Journal:  J Hematol Oncol       Date:  2015-05-10       Impact factor: 17.388
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.